Antitargets: Prediction and Prevention of Drug Side Effects (Methods & Principles in Medicinal Chemistry). Questo articolo non è disponibile.
Lingua: inglese
Editore: Wiley-VCH, 2008
- Rilegato
- Usato

Da: More Than Words, Waltham, MA, U.S.A.More Than Words
Venditore con 5 stelle
Venditore AbeBooks dal 30 novembre 2010
Non disponibile
Rilegato
Condizione: Usato - Buono
EUR 231,88
Descrizione dell’articolo da parte del venditore
. . All orders guaranteed and ship within 24 hours. Before placing your order for please contact us for confirmation on the book's binding. Check out our other listings to add to your order for discounted shipping.
Codice articolo WAL-A-6c-002015
- Titolo
- Antitargets: Prediction and Prevention of Drug Side Effects (Methods & Principles in Medicinal Chemistry)
- Editore
- Wiley-VCH
- Anno di pubblicazione
- 2008
- Condizione
- Good
- Rilegatura
- Rilegato
- Lingua
- inglese
- ISBN 10
- 3527318216
- ISBN 13
- 9783527318216
This practice-oriented handbook surveys current knowledge on the prediction and prevention of adverse drug reactions related to off-target activity of small molecule drugs. It is unique in collating the current approaches into a single source, and includes several highly instructive case studies that may be used as guidelines on how to improve drug development projects.
With its large section on ADME-related effects, this is key knowledge for every drug developer.
With its large section on ADME-related effects, this is key knowledge for every drug developer.
"Riassunto" può appartenere a un’altra edizione di questo titolo.
Informazioni sull’autore
Roy Vaz is the head of investigative pharmacokinetics at the Bridgewater, NJ (USA) location of Sanofi-Aventis Pharmaceuticals. He received his Ph.D. in Organic Chemistry from the University of Florida, Gainesville (USA), after graduating from the Indian Institute of Technology in Mumbai (India). Prior to his present appointment, he has worked with Bristol-Myers-Squibb and Tripos. He is a specialist on the prediction and modeling of cytochrome-mediated drug metabolism.
Thomas Klabunde obtained his PhD in chemistry from the University of Münster (Germany). After a postdoctoral fellowship at the Texas A&M University, he was appointed Assistant Professor at the Institute for Bioscience and Technology in Houston (USA). Later on, he joined the pharmaceutical research of Sanofi-Aventis in Frankfurt (Germany), where he is currently a group leader. His main interest lies with drug design approaches for G protein-coupled receptors, notably in the areas of lead finding and chemogenomics.
Thomas Klabunde obtained his PhD in chemistry from the University of Münster (Germany). After a postdoctoral fellowship at the Texas A&M University, he was appointed Assistant Professor at the Institute for Bioscience and Technology in Houston (USA). Later on, he joined the pharmaceutical research of Sanofi-Aventis in Frankfurt (Germany), where he is currently a group leader. His main interest lies with drug design approaches for G protein-coupled receptors, notably in the areas of lead finding and chemogenomics.
"Descrizione articolo" può appartenere a un’altra edizione di questo titolo.